Related Experiment Video
Updated: Jan 13, 2026
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Immunoliposome for Ewing Sarcoma
Daniel E Panosyan1, William S Panosyan2, Daron S Yacoubian2
1UCLA College of Letters & Science, University of California, Los Angeles, CA, U.S.A.; danielpanosyan@ucla.edu.
Background/Aim:
Metastatic Ewing sarcoma (EWS) causes high mortality. Precision medicine can help to mitigate dismal outcomes by targeted and more effective eradication of cancer cells. The aim of the study was to propose a targeted immunoliposome (IL) that has a potential of selectively binding to and destroying EWS cells. EWS expresses CD99 used for diagnostics. If CD99 is used for targeted IL, its payload must be more damaging to EWS than normal cells, which may also express CD99. Poly(ADP-ribose) polymerase (PARP) inhibitors are potential payload candidates, since they may enhance apoptosis of EWS-cells treated with DNA-damaging agents.
Materials And Methods:
The R2 genomics platform was used to explore the differential expression of CD99 and PARP1 in seven different databases (two EWS and five various normal tissues). Kaplan-Meier analysis was conducted for prognostic significance of PARP1 expression. The side-effect profile of PARP inhibitors allowed selection of a potential payload for proposed IL.
Results:
EWS samples (Savola/Surdez, n=196) had higher CD99 expression than 737 normal tissues. Endothelial compartment had twice-higher CD99 compared to other normal tissues but lower CD99 and PARP1 than EWS. Recurrent/metastatic EWS expressed more PARP1 than primary tumors (ANOVA p=0.02, Savola). Ten-year survival respectively for low versus high PARP1 expression was 36% vs. 14% for EFS (p=0.016), and 50% vs. 7% for OS (p<0.001). Normal hematopoietic/B-cell compartments had ≥2-times higher PARP1 than other tissues; therefore, niraparib (least lymphotoxic of PARP inhibitors), was favored as a payload for anti-EWS IL.
Conclusion:
Immunoliposomes covered with anti-CD99 mAbs and loaded with small-molecule niraparib may be developed as an adjuvant therapy for advanced EWS. Projected 100 nm IL should provide vascular permeability and tumor tropism; however, extensive preclinical evaluations will also be required regarding hematopoietic and endothelial damage.
Insights
This study proposes targeted immunoliposomes (IL) for metastatic Ewing sarcoma (EWS) treatment. Anti-CD99 IL loaded with niraparib show potential for selectively destroying EWS cells, offering a novel precision medicine approach.
Area of Science:
- Oncology
- Nanomedicine
- Precision Medicine
Background:
- Metastatic Ewing sarcoma (EWS) has a high mortality rate, necessitating advanced treatment strategies.
- Precision medicine offers targeted eradication of cancer cells, improving patient outcomes.
- EWS cells express CD99, a diagnostic marker, making it a target for therapies.
Purpose of the Study:
- To propose a targeted immunoliposome (IL) capable of selectively binding to and destroying EWS cells.
- To evaluate the potential of CD99 as a targeting ligand for IL in EWS therapy.
- To identify a suitable payload for ILs that is more cytotoxic to EWS than normal cells.
Main Methods:
- Utilized the R2 genomics platform to analyze differential expression of CD99 and PARP1 in EWS and normal tissues.
- Conducted Kaplan-Meier analysis to determine the prognostic significance of PARP1 expression in EWS.
- Selected a payload for the proposed IL based on the side-effect profile of PARP inhibitors.
Main Results:
- EWS samples exhibited higher CD99 expression compared to normal tissues; endothelial cells showed moderate CD99 expression.
- Recurrent/metastatic EWS demonstrated significantly higher PARP1 expression than primary tumors, correlating with poorer survival rates.
- Niraparib was selected as the payload due to its favorable side-effect profile, particularly its lower lymphotoxicity.
Conclusions:
- Targeted immunoliposomes featuring anti-CD99 antibodies and loaded with niraparib represent a promising adjuvant therapy for advanced EWS.
- The projected 100 nm IL size is expected to enhance vascular permeability and tumor tropism.
- Further preclinical evaluations are essential to assess potential hematopoietic and endothelial damage.
